SOAT1 and interstitial lung disease: JAK/STAT inhibition appears to control inflammation without worsening lung function, making it a promising dual-target strategy for selected CTD-ILD subsets, driven by clinical observations in anti-MDA5 dermatomyositis and encouraging results in refractory myositis-associated ILD [132].